| Ingredient | Amount Per Serving | % DV |
|---|---|---|
| Serving Size: 2 Capsules • Servings: 30 | ||
| Vitamin C (ascorbic acid) | 60 mg | 67% |
| Proprietary Blend: | 1,030 mg | * |
| Hesperidin | ||
| Apigenin | ||
| Disease Name | Score | Biological Process | Score | Pathway Name | Score | Biomarker | Score |
|---|---|---|---|---|---|---|---|
| Joint Pain |
|
Oxidative Stress & Damage | 31.13% | Oxidative Stress Pathway | 31.13% | ROSDown | 31.13% |
| Inflammatory Pain Signaling | 22.29% | COX-2 Synthesis | 16.34% | COX-2Down | 16.34% | ||
| Arachidonic Acid Metabolism | 5.94% | PGE2Down | 5.94% | ||||
| Neurogenic Pain & Nociception | 33.17% | PGE2 Signaling_1 | 16.50% | TRPV1pDown | 16.50% | ||
| PGE2 Signaling_2 | 16.67% | CGRPDown | 16.67% |
| Biological Process | Molecular Pathway | Biomarker | Direction | Control (nM) | Steady State (nM) | Basis |
|---|---|---|---|---|---|---|
| Oxidative Stress & Damage | Oxidative Stress Pathway | ROS | Down | 16.863 | 1.114 | simulated |
| Inflammatory Pain Signaling | COX-2 Synthesis | COX-2 | Down | 7.629 | 0.14916 | simulated |
| Inflammatory Pain Signaling | Arachidonic Acid Metabolism | PGE2 | Down | 1,932.050 | 1,242.961 | simulated |
| Neurogenic Pain & Nociception | PGE2 Signaling_1 | TRPV1p | Down | 0.05192 | 5.083e‑4 | simulated |
| Neurogenic Pain & Nociception | PGE2 Signaling_2 | CGRP | Down | 0.27659 | 1.627e‑9 | simulated |
.video-placeholder div above — add class has-video to hide the overlay.
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. CytoSolve® scores represent computational modeling outputs based on peer-reviewed research and do not constitute medical advice. Individual results may vary. Always consult a healthcare professional before starting any supplement regimen. Patent No.: US 17/011,83. mV25™ is a trademark of VASHIVA, LLC.
Beta Release Sign Up
Submit the Form Below to Receive Early Access to Gods.com